Price (delayed)
$2.47
Market cap
$515.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$502.38M
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
There are no recent dividends present for SGMO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.